Using Unani Medicine to Manage Polycystic Ovarian Syndrome
Effect of Unani Medicine Coded Formulations for the Management of Anomalies Associated With Polycystic Ovarian Syndrome
This study is testing if Unani medicine can help women with Polycystic Ovarian Syndrome manage their symptoms better than current treatments.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 38 Years |
| Sex | Female |
| Sponsor | Hamdard University Academic / other |
| Locations | 1 site (Karachi, Sindh) |
| Trial ID | NCT06199544 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of Unani medicine as an alternative treatment for managing symptoms associated with Polycystic Ovarian Syndrome (PCOS). It aims to address the limitations of current medications, particularly metformin, which can cause side effects. The study will involve women diagnosed with PCOS based on specific criteria and will assess the impact of Unani medicine on their symptoms. The goal is to provide a holistic approach to managing this common endocrine disorder.
Who should consider this trial
Good fit: Ideal candidates for this study are women of reproductive age diagnosed with PCOS who meet the Rotterdam criteria.
Not a fit: Patients with severe adverse drug reactions or other significant medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a new, effective treatment option for women suffering from PCOS with fewer side effects.
How similar studies have performed: While there is limited research on the use of Unani medicine for PCOS, other studies have explored alternative treatments with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria No complications record of reproductive system, 4) PCOS diagnosed using Rotterdam criteria fulfilling any two of the following: (i) Menstrual irregularity or oligo-/anovulation, (ii) Hyperandrogenism (clinically and/or biochemically), (iii) Polycystic appearance on ultrasound Exclusion criteria 1) Patients with severe adverse drug reactions, 2) Record of cardiovascular, diabetes, hepatic and neoplastic disorders or other concurrent medical illnesses, 3) Hormonal contraceptive used within 6 months, or anti-obesity drugs within 3 months of the study, 4) Irregular menstrual bleeding other than PCOS and 5) Positive pregnancy test.
Where this trial is running
Karachi, Sindh
- Shifa ul mulk memorial hospital — Karachi, Sindh, Pakistan (Recruiting)
Study contacts
- Study coordinator: Leena Hameed, M.Phil.
- Email: Leena.hameed@hotmail.com
- Phone: 00923333037145
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.